Registry update — unassessed
COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 14, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report what outcomes were measured or what the actual results were, making it impossible to determine whether fisetin had any effect on disease progression or inflammation.
- Sample size is not reported, limiting assessment of statistical power.
- Only a Phase 2 pilot study in hospitalized patients; results would not establish efficacy in other populations or settings.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Hospitalized adults with SARS-CoV-2
- Primary outcome
- Prevention of increase in disease progression and alleviation of complications of coronavirus due to excessive inflammatory reaction
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Oct 14, 2025
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.